Comparative Pharmacology
Head-to-head clinical analysis: OPHTHOCHLOR versus RAXAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPHTHOCHLOR versus RAXAR.
OPHTHOCHLOR vs RAXAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
RAXAR (revumenib) is a selective inhibitor of the menin-KMT2A protein-protein interaction. By binding to menin, it blocks the interaction with KMT2A (MLL1), thereby disrupting the transcription of oncogenic genes such as HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemic cells.
Chloramphenicol 0.5% ophthalmic solution: Instill 1-2 drops into the affected eye(s) every 3-4 hours for 7-10 days. For severe infections, every 2 hours initially. Ointment: Apply a small amount (about 0.5 cm) into the conjunctival sac every 3-4 hours.
Subcutaneous injection: 200 mg once daily, irrespective of timing of meals.
None Documented
None Documented
5-6 hours in normal renal function; prolonged up to 24-48 hours in severe renal impairment
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 25 hours).
Renal: 70-80% unchanged; biliary/fecal: 20-30%
Primarily hepatic metabolism; renal excretion of unchanged drug <5%; biliary/fecal elimination as metabolites accounts for >90% of total clearance.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic